NeoGenomics, Inc.

NasdaqCM:NEO Stock Report

Market Cap: US$1.0b

NeoGenomics Management

Management criteria checks 1/4

NeoGenomics' CEO is Tony Zook, appointed in Apr 2025, has a tenure of 2.83 years. total yearly compensation is $9.35M, comprised of 6.4% salary and 93.6% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $1.17M. The average tenure of the management team and the board of directors is 1.1 years and 5.3 years respectively.

Key information

Tony Zook

Chief executive officer

US$9.3m

Total compensation

CEO salary percentage6.43%
CEO tenure1yr
CEO ownership0.1%
Management average tenure1.1yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

NeoGenomics: Distribution Moat In Community Oncology

Jan 25

Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt?

Aug 27
Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt?

Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower

Jul 30
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower

Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper

May 23
Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper
User avatar

PanTracer Launch And MRD Collaboration Will Strengthen Future Cancer Testing Leadership

NeoGenomics' strategic investments and collaborations are expected to enhance customer experiences, boost test volumes, and strengthen competitive positioning in MRD monitoring and Heme testing.

NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors

Mar 08
NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors

NeoGenomics: Decent Fundamentals, But Still Overvalued

Feb 28

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Feb 18
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash

Jan 14
What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash

NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Nov 23
NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Aug 01
Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Jul 15
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Mar 30
Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

CEO Compensation Analysis

How has Tony Zook's remuneration changed compared to NeoGenomics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$9mUS$602k

-US$108m

Sep 30 2025n/an/a

-US$113m

Jun 30 2025n/an/a

-US$104m

Mar 31 2025n/an/a

-US$78m

Dec 31 2024US$320kn/a

-US$79m

Sep 30 2024n/an/a

-US$78m

Jun 30 2024n/an/a

-US$79m

Mar 31 2024n/an/a

-US$84m

Dec 31 2023US$276kn/a

-US$88m

Compensation vs Market: Tony's total compensation ($USD9.35M) is above average for companies of similar size in the US market ($USD3.55M).

Compensation vs Earnings: Tony's compensation has increased whilst the company is unprofitable.

CEO

Tony Zook (64 yo)

1yr
Tenure
US$9,348,604
Compensation

Mr. Anthony P. Zook, also known as Tony, serves as an Independent Director at Adaptin Bio Operating Corporation since February 2025. He is CEO of NeoGenomics, Inc. from April 1, 2025 and has been its Direc...

Leadership Team

NamePositionTenureCompensationOwnership
Anthony Zook
CEO & Director1yrUS$9.35m0.12%
$ 1.2m
Warren Stone
President & COO1yrUS$5.07m0.12%
$ 1.2m
Elizabeth Floegel
Chief Digital & Information Officer1.3yrsUS$278.63k0.018%
$ 181.4k
Alicia Olivo
Executive VP of Business Development4yrsUS$3.05m0.072%
$ 716.9k
Gary Passman
Chief People & Culture Officerno dataUS$2.44mno data
Abhishek Jain
Executive VP & CFOless than a yearno datano data
Gregory Aunan
Senior VP & Chief Accounting Officer2.9yrsno data0.017%
$ 169.4k
Kendra Sweeney
Vice President of Investor Relations & Communicationsno datano datano data
Clarence Cooper
Vice President of Compliance & Privacyless than a yearno datano data
Kareem Saad
Head of Strategy2.3yrsno datano data
Andrew Lukowiak
Chief Innovation Officerno datano datano data
Priya Vedaraman
Senior Vice President of Financeno datano datano data
1.1yrs
Average Tenure
50.5yo
Average Age

Experienced Management: NEO's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Anthony Zook
CEO & Director2.8yrsUS$9.35m0.12%
$ 1.2m
Michael Kelly
Independent Director5.8yrsUS$319.68k0.038%
$ 376.9k
David Perez
Independent Director3.4yrsUS$319.30k0.034%
$ 337.5k
Lynn Tetrault
Independent Chair of the Board10.8yrsUS$365.15k0.062%
$ 620.2k
Bernard Fox
Member of Scientific Advisory Board5.3yrsno datano data
Riccardo Dalla-Favera
Member of Scientific Advisory Board5.3yrsno datano data
Steven Rosen
Member of Scientific Advisory Board5.3yrsno datano data
James Downing
Member of Scientific Advisory Board5.3yrsno datano data
Stephen Kanovsky
Independent Director8.8yrsUS$302.92k0.040%
$ 402.5k
Razelle Kurzrock
Member of Scientific Advisory Board5.3yrsno datano data
Alison Hannah
Member of Scientific Advisory Board5.3yrsUS$418.58k0.10%
$ 1.0m
Mark Rubin
Member of Scientific Advisory Board5.3yrsno datano data
5.3yrs
Average Tenure
65yo
Average Age

Experienced Board: NEO's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/13 11:45
End of Day Share Price 2026/04/13 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NeoGenomics, Inc. is covered by 25 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Raymond MyersBenchmark Company
Michael RyskinBofA Global Research